Bitopertin
investig.
What it isGlycine transporter type 1 inhibitor; failed in schizophrenia, now studied in erythropoietic protoporphyria.
Why this oneRaising synaptic glycine was the leading strategy for NMDA hypofunction in schizophrenia.
What limits itThe phase 3 schizophrenia program failed, which reframed the whole glycine hypothesis. Investigational only.
FDA-approved for
- schizophrenia (failed trials) / erythropoietic protoporphyria (investigational)
Off-label
- erythropoietic protoporphyria (phase 3)
- schizophrenia (failed phase 3)
NO BOXED WARNINGS
Principal riskThe schizophrenia program failed in phase 3
Classes and tags
Clinical profile
Mechanism of action: Bitopertin ballicule
